* Note: Prices are in Million (M) USD.
Description:
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $229 M
Debt : $2,986 M
EBITDA : $546 M
Net Debt (Debt - Cash): $2,757 M
Since EBITDA cannot cover net debt within 3 years, Avoid This Stock.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Diagnostics & research
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 15.82
Since Forward PE Ratio is between 15 - 20, 3 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 20 overlapping fiscal years (max 20).Average Free Cash Flow: $231 M
Average Revenue: $2,012 M
Revenue Converted To Free Cash Flow (%): 11.5%
Since Free Cash Flow (FCF) to Revenue percentage is less than 15, 1 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $4,050 M
Revenue 4 Years Ago (2020-12-31): $2,924 M
Last 5 Years Average Revenue Growth: 8%
Since Revenue Growth is between 5 - 10, 2 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $52 M
Share Count 5 Years Ago (2020-12-31): $51 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $10.50
Trailing 12-Month Earnings Per Share (EPS): $10.15
Average Earnings Per Share (EPS): $10.33
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 20 valid ROE years (max 20).Average ROE: 7.3%
Since Average ROE is less than 10, 1 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $163
52-Week Low: $92
Threshold Price (15% Above 52-Week Low): $106
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $8,198 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Value-Trade has assigned 11 points to above Charles River Laboratories (CRL) stock.
Last 20 Years Avg PE 19.6, Fair Value PE 12, Industry Based PE 18, Growth Based PE 7, RCFC Based PE 21.2, ROE Based PE 15.84, Risk-Free Anchored PE (25% MoS) 17.08. Based on these 7 values, average assigned is 15.82. Value-Trades has assined P/E value 15.82. Since an average (Current Year EPS + Next Year EPS) earning per share is $10.325.
The fair value of Charles River Laboratories (CRL) stock should be (15.82 x $10.325) = $163.32.
